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Brain protein biomarker clearance to blood in traumatic brain injury (TBI) is not fully 
understood. The aim of this study was to analyze the effect a disrupted blood-brain barrier 
(BBB) had on biomarker clearance. Seventeen severe TBI patients admitted to Karolinska 
University Hospital were prospectively included. Cerebrospinal fluid (CSF) and blood 
concentrations of S100B and neuron-specific enolase (NSE) were analyzed every 6-12 hours 
for approximately one week. Blood and CSF albumin were analyzed every 12-24 hours, and 
BBB integrity was assessed using the CSF:blood albumin quotient (QA). We found that time-
dependent changes in the CSF and blood levels of the two biomarkers were similar but the 
correlation between the biomarkers and QA was lower for NSE (r=0.444) than S100B 
(r=0.668). Since data was longitudinal, we also conducted cross correlation analyses, which 
indicated a directional flow and lag-time of biomarkers from CSF to blood. For S100B, this 
lag-time could be ascribed to BBB integrity, whereas for NSE it could not. Upon inferential 
modelling, using generalized least square estimation (S100B) or linear mixed models (NSE), 
QA (p=0.045), time from trauma (p<0.001), time from trauma2 (p=0.023) and CSF biomarker 
levels (p=0.008) were independent predictors of S100B in blood. In contrast, for NSE, only 
time from trauma was significant (p<0.001). These findings are novel and important, but must 
be carefully interpreted because of different characteristics between the two proteins. 
Nonetheless, we present the first data that indicates that S100B and NSE are cleared differently 
from the central nervous system, and that both the disrupted BBB and additional alternative 
pathways, such as the recently described glymphatic system, may play a role. This is of 
importance both for clinicians aiming to utilize these biomarkers and for the pathophysiological 
understanding of brain protein clearance, but warrants further examination. 
 




Traumatic brain injury (TBI) is one of the most common causes of death and disability,1 
afflicting around 10 million people annually.2 Unconscious TBI patients deemed to be in need 
of intracranial monitoring are treated in neuro-critical care units (NCCUs).3 Here, different 
modalities are monitored in order to prevent secondary insults that may lead to irreversible 
deterioration in the already damaged brain.4-6 Among these modalities, brain enriched proteins 
of tissue fate (i.e. “biomarkers”) are increased in body fluids following brain injury and have 
become increasingly used in the management of TBI.7 The two most studied protein 
biomarkers include the primarily astrocytic S100B and the neuronal neuron-specific enolase 
(NSE). Even though neither is brain-specific, both are highly brain-enriched and have been 
associated with a worse intracranial condition and long-term functional outcome following 
TBI.8-10 In fact, some centers event utilize one or both in clinical routine work 11, 12, hence 
making these two “biomarkers” of particular interest to the neurotrauma translational research 
field.   
 
The clearance mechanism of protein biomarkers from brain to blood is not fully understood 
but is of importance for clinical interpretation and pathophysiological understanding. The adult 
central nervous system (CNS) comprises three anatomical barriers, namely: (i) the blood-
cerebrospinal fluid (CSF) barrier, (ii) the blood-brain barrier (BBB), and (iii) the arachnoid 
barrier.13 For simplicity, and to align with the clinical research field, we refer to all of these 
barriers as “BBB”. In addition, a transport route denoted the glymphatic system has recently 
been described in experimental models.14 While it has been suggested in preclinical models 
that brain enriched proteins in CSF passively leave the brain through this peri-vascular 
“glymphatic” system,15 others claim that the BBB integrity plays a more decisive role.16-18 In 
 
TBI studies, where the patient likely suffers from concomitant injuries to multiple CNS 
barriers, the gold-standard strategy for assessing BBB disruption (BBBD) is the CSF to blood 
albumin quotient (QA).19-25 Previous studies of TBI and subarachnoid hemorrhage assessing 
how serum levels of S100B are associated with QA have not shown significant correlations.23, 
26 However, these studies have been limited by a lack of longitudinal analyses and high 
frequency sampling during constant CSF drainage. The trajectory of secondary 
pathophysiological mechanisms following TBI likely require a high temporal resolution,3 
multi-compartment monitoring, and modeling to elucidate biomarker and QA dynamics. In 
aggregate, how brain enriched proteins leave the injured brain warrants further research as it 
may increase our understanding of brain injury pathophysiology in several conditions and 
improve the utility of biomarkers in clinical decision making.  
 
Aim 
We aimed to assess if, and how, clearance of brain enriched proteins (S100B and NSE) from 
brain to blood is affected by BBBD, measured as QA, over time utilizing a high-sampling 




Materials and Methods 
The included patients were part of a prospective observational study27 undertaken at the NCCU 
at Karolinska University Hospital (Stockholm, Sweden) between January 1st 2010 and March 
1st 2013. Written, informed consent was acquired from next-of-kin. The study was conducted 
in accordance with the Declaration of Helsinki and Swedish law. Ethical approval was provided 
by the Stockholm County branch of the Central Ethical Review Board (#2009/1112-31/3), now 
called the Swedish Ethical Review Authority.  
 
Sample size calculation 
Sample size estimation a priori using power analysis was unfeasible since no assumptions on 
effect size to our knowledge have been described in the literature using the same approach as 
in our study. However, using data from our group,26 we could estimate our sample sizes for a 
cross-sectional rather than a longitudinal data set. Aiming for a correlation coefficient r = 0.60 
between S100BCSF and S100Bblood we found the estimated sample size needed to reach 80% 
power on the 0.05 significance level (one-sided test) using the R28 package pwr29 to be n = 15 
patients. The effect size estimate was larger than the one previously reported from our group 
(r = 0.45),26 but smaller than what has more recently been reported30 (r = 0.79), leading us to 




Due to sporadic availability of research personnel, recruitment was made periodically. Patients 
were not randomized, since no group-specific interventions were conducted. Inclusion criteria 
 
for the patients were as follows: i) age 18-75 years, ii) Glasgow Coma Scale (GCS) 3-8 
(unconscious at admission), iii) computerized tomography (CT) verified structural 
intraparenchymal intracranial injury. Exclusion criteria comprised: i) GCS 3 and bilaterally 
non-responsive pupils, ii) slit ventricles (since that would preclude the planned patient study 
management, by making external ventricular drain (EVD) insertion impossible), iii) patient 
with un-survivable injury, iv) unconsciousness of etiology other than TBI, v) absence of CT 
verified intraparenchymal intracranial injury, vi) other concurrent systemic terminal disorder, 
vii) patients that would be impossible to follow-up (e.g. foreign citizens).  
 
Patient Management and Sample Acquisition 
The detailed study setup has been described previously.27 Briefly, upon admission, patients 
received an EVD. The drain was connected to a four-way stopcock (Multiflo 3, BD, Connecta, 
Franklin Lakes, NJ, USA), connected to a LiquoGuardâ CSF-pump (Möller Medical GmbH, 
Fulda, Germany) set to a constant drainage velocity of 2 mL CSF per hour. CSF was collected 
in, and samples were obtained from, the drainage bag in the LiquoGuardâ system in order to 
minimize the risk for infections, and freeze blocks were used to keep the CSF cold in order to 
limit protein degradation. The collected pool of CSF and readily acquired arterial blood, were 
analyzed in 6-and 12-hour intervals, for both S100B and NSE. Albumin (plasma and CSF) was 
analyzed once to twice daily. S100Bblood was analyzed by electrochemiluminescence 
immunoassay (Elecsys, Roche Diagnostics, Basel, Switzerland), albuminplasma by colorometric 
BCP-binding assay and albuminCSF by immunoturbitity on a Roche Cobas/Modular platform 
(Roche Diagnostics, Basel, Switzerland). NSEblood, NSECSF, and S100BCSF were analyzed by 
immunoluminometric assay on a LIAISON XL system (DiaSorin, Saluggia, Italy). S100Bblood 
and S100BCSF were analyzed on different platforms due to local procurements and inability to 
 
run CSF samples on the more modern Cobas/Elecsys platforms. Each individual assay has 
shown robust within- and between-run similarity,31 thus enabling longitudinal sampling as 
employed in this study. Some claim the different platforms are not entirely interchangeable,32 
whereas others have found excellent associations between the methods (r = 0.932).31 Of note, 
to our knowledge no studies have examined bi-compartmental similarities (i.e. between CSF 
and blood). This is of importance, since absolute between-assay agreement is of greater 
importance when identical samples from the same compartment are examined on multiple 
platforms. However, for the scope of this study the relative relationship was of greater interest. 
All laboratory assays were performed at the Karolinska University Laboratory in accordance 
with local guidelines. Aside from this, patients were treated in accordance with local routine at 
the NCCU, as previously described.8 
 
Clinical Parameters  
Baseline clinical data was defined and acquisitioned as follows. Clinical variables comprised 
GCS,33 (head and non-head) Abbreviated Injury Scale34 (AIS), injury severity score35 (ISS), 
and significant multitrauma,36 all of which were acquired upon hospital admission. Of note, an 
AIS of 6 at admission is impossible, as it denotes an un-survivable injury. CT variables upon 
admission were graded using the Marshall CT Classification,37, 38 where classifications V and 
VI were collapsed into one category (“mass lesion”) as we used only the admission CT. For 
comparison, we also assessed the Rotterdam-39 and Stockholm CT scores.40 Radiologic brain 
injury progression upon subsequent examination was evaluated employing a similar strategy 
as in previous work.8, 41 Glasgow Outcome Scale42 (GOS) was assessed as described 
previously.27 In short, a neuro-rehabilitation board-certified physician (PHG) examined 
 
patients 6 months following the TBI. GOS comprises 5 categories, namely 1) dead, 2) persistent 
vegetative state, 3) severe disability, 4) moderate disability, and 5) low disability.  
 
Definitions 
We used “BBBD” as a comprehensive term to denote all types of barrier disruption that can be 
discerned following TBI, including disruption of the anatomical BBB as well as the blood-CSF 
barrier.43 BBBD was defined as the quotient between CSF and blood albumin (Equation 1), 
since that constitutes the literature gold-standard.19, 24, 43 The reference intervals used for all 
proteins in the current study were defined using reference intervals stipulated by the Karolinska 





[INSERT TABLE 1] 
Statistical analysis 
Statistical analyses were conducted using R,28 through the interface RStudio®. Continuous data 
was presented as mean ± standard deviation (SD) if normally distributed, or else median 
(interquartile range [IQR]). Categorical data was presented as count (%). In graphical 
depictions and calculations, biomarker values were converted to log10-transformed values, 
unless otherwise stated. A p value £ 0.05 or a 95% confidence interval (CI), where the range 
of the CI did not contain the value 0, were considered significant. 
 
Several variables were sampled at different time intervals, resulting in time points without 
sample overlap. This is demonstrated graphically48 (Supplementary Figure 1). Following a 
 
comparison between linear and locally weighted scatterplot smoother interpolation 
(Supplementary Figure 2), this was compensated for by linear interpolation. Data rows that still 
retained “missing” values for a certain time point due to consecutive non-overlapping sampling 
time points were handled by complete case analysis. 
 
Correlations (regular correlations are here referred to as “momentary” correlations) between 
biomarkers in different compartments and QA were assessed using repeated measures 
correlation49 on log10-transformed variables in order to obtain linear relationships. Each model 
was examined with regard to relevant assumptions. The R packages rmcorr50 and tidyverse51 
were used for calculations and graphical depictions. Since biomarker levels in different body 
compartments might correlate in a time-delayed fashion, we also cross correlated the original 
data. We abstained from detrending or differencing the data since the relationship we examined 
was the underlying shared time trend. For all, the biomarker sampling time points were 
subdivided into defined time intervals (“lags”) of 0.5 days (12 hours). Multiple measurements 
occurring within one lag were averaged. Last, cross correlation was conducted per patient, 
whereupon results were pooled for all patients and lags. For all cross correlations, original data 
(i.e. not log10-transformed) were used. 
 
For inferential analysis we compared a general linear model with correlated errors (general 
least square estimation, a so called “marginal model”) and a linear mixed model. For both, the 
nlme package in R was used.52 Independent of analysis type we modelled a within-patient 
variance-covariance matrix since we used repeated-measures data. The variance-covariance 
matrix was constructed as a time series model, for which we determined stationarity, 
autocorrelation, and partial autocorrelation. We deemed that the data was stationary using the 
 
Kwiatkowski-Phillips-Schmidt-Shin test and therefore abstained from autoregressive 
integrated moving average modelling.53 The variance-covariance matrix hence consisted of an 
autoregressive-moving average (ARMA) model. We tested 25 different ARMA combinations 
of varying complexity, and then chose the optimal ARMA structure based on Akaike 
Information Criterion. For both S100B and NSE we used a 1st order autoregressive model with 
a moving average of 1, i.e. ARMA(p =1, q=1) . The resulting models were validated 
graphically.54 For general linear as well as linear mixed model selection we employed both a 
step-up55 and a top-down strategy.56 Random effect structures were evaluated using restricted 
maximum likelihood-based estimations and fixed effects structure using maximum likelihood 
estimations. Model selection was conducted by likelihood ratio tests between nested models 
and Type I F-tests. P-values of the final models were generated using Satterthwaite 
approximations in the R package lmerTest.56, 57 In all analyses, the dependent variable was the 
biomarkerblood value (log10 transformed). For S100B, the first 12 hours were excluded from 
analysis, since these time points have been associated with an “extracranial peak”.8, 9 In general, 
Akaike Information Criterion was lower for the mixed model design in the top-down strategy, 
whereas they were equal in the step-up strategy. For S100B, the variance-covariance matrix 
generated in the linear mixed model was not positive-definite, which is why we chose to use 
the equivalent marginal model for S100B.56 For NSE, we had no such issues, which is why we 
present results from the linear mixed model. Of note, results were highly similar independent 
of linear mixed or marginal model design for each biomarker. Model assumptions were 
examined graphically with regard to homogeneity of variances, normality of variances, 
correlation between fitted and observed values, and individual assessment of residual 
autocorrelation and partial autocorrelation. For NSE, one patient (pat #17) followed a markedly 
different trajectory compared with the other patients and also consisted an outlier using the 
model diagnostics above. For validation, the results for NSE were run both including and 
 
excluding pat#17 and the results were to a large extent similar, leading us to conclude that the 




In total, 17 patients were recruited, of which one patient was excluded since no samples of CSF 
albumin had been obtained. Among included patients, there was no loss-to-follow up. 
Demographics are depicted both individually (Table 2) and for the whole cohort 
(Supplementary Table 1). Patients were predominantly middle-aged males, with a median GCS 
of 7 (4-7). Around 40 % of the patients had suffered a significant multi-trauma. However, the 
majority of patients had a head AIS score of 5, suggesting that a severe cranial trauma 
constituted the predominant pathology. Of all patients, 31.3 % had progression of CT verified 
lesions during the study period. On long-term follow-up, half of the patients suffered an 
unfavorable outcome (GOS 1-3).  
 
[INSERT TABLE 2] 
 
All patients exhibited profoundly increased values of S100B in CSF and blood following 
trauma (Figure 1A, C), all higher than the 0.11 µg/L cut-off used to screen if mild TBI patients 
have an intracranial lesion. A majority of patients also exhibited NSE CSF and blood 
concentrations above the upper reference intervals of 13 µg/L (CSF) and 18 µg/L (blood) 
(Figure 1B, D). Roughly half of the patients demonstrated a disrupted BBB as defined by QA 
above 0.006-0.009 (Figure 1F) upon admission, closely mimicked by CSF levels of albumin 
above 260-400 mg/L (Figure 1E), but not by blood albumin (Figure S3). Even though the QA 
slope showed a group-wise decreasing trend over time, the study period of about one week was 





Correlations between biomarkers and QA  
In order to elucidate the relationship between biomarkers in different compartments and QA, 
we conducted both regular (here denoted “momentary”) correlation and cross correlation 
analyses. Cross correlation analyses were conducted since clearance from CNS to peripheral 
blood might occur with a time delay. For cross correlations, we examined three temporal 
relationships, namely: i) correlation between biomarkerCSF values and BBBD (Figure 2A, D); 
ii) correlation between biomarkerblood values and BBBD (Figure 2B, E); and iii) cross 
correlation between biomarkerCSF and biomarkerblood values (Figure 2C, F). 
 
[INSERT FIGURE 2] 
 
There was a strong positive (momentary) correlation between S100BCSF and S100Bblood (r = 
0.667, CI 0.602-0.723) as well as QA and S100Bblood (r = 0.668, CI 0.598-0.728). Cross 
correlations for S100B showed that there was an immediate correlation between BBBD and 
S100BCSF (Figure 2A), whereas there was a lagged relationship between S100BCSF and 
S100Bblood (Figure 2C). The lag was attributed to the identically lagged relationship between 
BBBD and S100Bblood (Figure 2B). Hence, S100B exhibited a delayed release to blood, which 
occurred concomitantly to a delayed leakage across the BBB. 
 
 
There was also a positive (momentary) correlation between NSECSF and NSEblood (r = 0.436, 
CI 0.343-0.521) as well as QA and NSEblood (r = 0.444, CI 0.345-0.533). NSE cross correlations 
demonstrated a negative lag between BBBD and NSECSF (Figure 2D) indicating that NSECSF 
levels increased more swiftly than the BBBD occurred following an injury. NSECSF and 
NSEblood (Figure 2F) were positively lagged against one another, meaning that there is a period 
of delay before NSE can be detected in blood. This phenomenon could not be attributed to the 
relationship between BBBD and NSEblood (Figure 2E), since these exhibited a peak correlation 
at lag 0, i.e. immediate to one another.  Hence, there was a discrepancy between NSECSF and 
NSEblood lags (+2), not accounted for by the other cross correlations (-1 and 0 lags respectively). 
Further, this means that the delayed NSE clearance did not seem to be a consequence of a 
delayed intracranial NSE de novo release, i.e. higher CSF levels (Figure 2D), or due to a slower 
clearance across the disrupted BBB (Figure 2E, lag 0-2). 
 
In summary, a measured blood biomarker concentration is presumably a reflection of both 
momentary brain clearance, delayed ditto, as well as the extent of the different disintegrated 
CNS barrier components. For momentary correlations, there was a stronger correlation 
coefficient for S100B compared with NSE. Generally, there were only small differences 
between the two biomarkers over the different cross correlations. However, some noteworthy 
disparities were found. NSE exhibited fewer lags with significant cross correlations (Figure 
2D-F) than S100B (Figure 2A-C). Hence, NSE overall demonstrated a less robust pattern than 
did S100B, why the NSE results should be interpreted cautiously. Moreover, in contrast to 
S100Bblood, the disintegrated barrier cannot solely explain the temporal pattern of NSE 
clearance. This is manifested throughout lag 0-2 (equivalent to 0-24 hours) (Figure 2E), where 
there however are small differences in mean cross correlation and the confidence intervals are 
very broad, why these findings should be interpreted with caution.  
 
 
Modelling of biomarker clearance from CSF to blood 
In order to inferentially determine the importance of QA for blood biomarker levels we 
conducted a generalized least square linear model (marginal model) for S100B (Figure 3A, 
Table 3) and a linear mixed effects model for NSE (Figure 3B, Table 3).  
 
[INSERT FIGURE 3] 
 
All models used time from trauma and CSF biomarker levels as covariates together with a 
predetermined correlation structure, thereby accounting for the longitudinal study design. 
Interestingly, there were notable differences between the biomarkers. For S100B (Table 3, 
Figure 3A), S100Bblood values could be modelled as a function of time from trauma, S100BCSF 
and QA, all of which were significant. As can be seen in Figure 1C, the relationship followed a 
curvilinear slope, making the quadratic time from trauma term significant as well. The finding 
that QA is a predictor of S100Bblood suggests that the extent of BBBD is related to the levels of 
S100B in blood.  
[INSERT TABLE 3] 
 
In contrast, for NSE (Table 3, Figure 3B) only time from trauma emerged as a significant 
independent predictor, but neither NSECSF nor QA. These findings were robust even when 
checking for more complex statistical structures, such as interaction effects. In aggregate, these 
findings, and the contrast between the biomarkers, indicate that BBBD might affect biomarker 
clearance from CSF to blood differently for different proteins.  
 
Discussion 
We present a high temporal resolution, multi-compartment, prospective biomarker monitoring 
study conducted after severe TBI. We examined how BBBD, measured as QA, affects brain 
clearance of the two most studied protein biomarkers in TBI. We found clear correlations 
between the blood biomarker values and QA, but coefficients were notably larger for S100B. 
We also found a cross correlation between the CSF biomarker and the blood biomarker levels 
for both S100B and NSE, indicative of a slightly delayed/”lagged” clearance from CSF to blood 
that for S100B, but not NSE, co-varied with a delayed clearance across the BBB. Finally, 
regression modelling demonstrated that for S100B, time from trauma, S100BCSF and QA were 
important contributors to S100Bblood. In contrast, only time from trauma emerged as a 
significant predictor of NSEblood. We suggest that one reason for the discrepancies between the 
two biomarkers is that they are cleared differently, with S100B being cleared through a 
disrupted BBB unlike NSE, but this warrants further examination. 
 
The disrupted blood-brain barrier in TBI  
We assessed how a trauma-induced BBBD affects brain biomarker concentrations in blood. 
Even though some radiologic techniques have been proposed to quantify BBBD,58, 59 QA 
remains the gold standard assessment,19-25 since the 67 kDa protein albumin lacks intracranial 
synthesis,19 is not catabolized in the CNS,60 and has a 200 times lower concentration in CSF 
compared with serum.19 We found that while QA on a group-basis had a decreasing trend over 
the first week, patients who had normal QA values at study onset maintained normal values 
throughout the study period and vice versa. Kleindienst et al also found persistently deranged 
QA values in a cohort of TBI and subarachnoid hemorrhage (SAH) patients.23 In contrast, 
Bellander and co-workers found a steep normalization of QA within the first week after TBI,26 
 
congruent with data from Blyth and colleagues.20, 21 This indicates that the BBB is likely more 
affected by the primary injury than secondary insults, and that BBBD may persist for at least 7 
days, or as some have suggested, even longer.61 Consistently, some patients did not exhibit any 
signs of BBBD in our study. The underlying reason for this cannot be causally determined by 
this work, due to the small sample size, but we hypothesize that differences in the intracranial 
injury panorama is a probable explanation. This finding further highlights the necessity to 
individualize treatment following TBI. Finally, we noticed that QA and albuminCSF mimicked 
each other closely. Thus, albumin levels in CSF are presumably enough to assess the BBBD, 
though this still necessitates CSF sampling, which is not always feasible in the clinical setting.   
 
Correlation analyses of biomarkers and QA 
We found that S100Bblood was momentarily correlated to S100BCSF and QA, in accordance with 
previous studies.20, 21, 26, 30, 59 Others have acquired contrasting results,23, 26 possibly due to 
different analysis strategies. We also noted that momentary NSEblood levels were correlated 
with NSECSF and QA, something that has been shown in non-TBI studies,60, 62 while a previous 
TBI study did not show this association.26 For both biomarkers, we noted similar correlation 
coefficients between CSF:blood and blood:QA. This implies that a third covariate, most likely 
time from trauma, inferred these values. We therefore performed cross correlations, to elucidate 
the underlying share time-trend of the biomarker correlations. 
 
In our cross correlations, we noted that both S100B and NSE exhibited peak CSF:blood cross 
correlations at lags > 0, suggesting that both biomarkers have a partially delayed clearance 
from CSF to blood. Previous studies examining S100Bserum and S100BCSF correlation have 
found a delay varying between 0-24 hours30 and 48 hours.63 Our S100B CSF:blood cross 
 
correlation exhibited a lag of approximately 12 hours, corresponding to the delay seen between 
QA and S100Bblood. Hence, the CSF:blood and the QA:blood pattern mimicked each other, 
presumably indicating that there is a brief initial accumulation of S100B in CSF before 
clearance through a disrupted BBB. This constitutes a tentative pathway for S100B clearance 
to peripheral blood. In contrast, NSE exhibited a more delayed peak in cross correlations 
compared with S100B (approximately 24 hours). This is important, since a brain biomarker of 
tissue fate should confer accurate and timely information if it is to aid in clinical decision-
making. Moreover, in the three cross correlations performed on NSE, de novo release of 
NSECSF seemed to occur more swiftly than BBBD, and BBBD occurred simultaneously to 
NSEblood detection. Hence, there was a delayed clearance of NSE from CSF to blood, that was 
not mimicked by either CSF:QA or QA:blood cross correlations which was the case for S100B. 
Data was scarce for all of these observations, but if true this means that neither delayed BBB 
clearance nor delayed de novo release of NSE could explain the delayed clearance of NSECSF 
to blood. Hence, there is a weak but interesting signal suggesting that intracranial NSE 
accumulates and thereafter is cleared through a route other than the BBB. One tentative 
clearance pathway is the experimentally described glymphatic system,14 suggested to be a 
clearance route for both NSE and S100B.15, 64 Another possible route includes the recently 
discovered lymphatic vascular network surrounding dural sinuses which drains in deep cervical 
lymph nodes and subsequently blood, with clearance of proteins from the brain interstitium.65, 
66 The strong momentary correlations we see between CSF and blood suggests a relatively 
direct pathway in the likes of these glymphatic/brain lymphatic routes, which in the case of 
NSE is seemingly independent of BBBD. However, it should be noted that both the glymphatic 
and brain lymphatic vasculature currently only have been sufficiently studied in animal models. 
Some promising work using magnetic resonance imaging speak in favor of the existence and 
 
importance of the glymphatic system in humans,67, 68 but larger human studies and functional 
characterizations are still warranted. 
 
Blood-brain barrier disruption predicts S100B but not NSE concentrations in blood 
For inferential analysis, we employed marginal and linear mixed modelling. For S100Bblood, 
we found that QA, S100BCSF, and time from trauma were significant independent predictors. 
This indicates that S100B is dependent upon the BBB for clearance to peripheral blood, but 
also that S100Bblood cannot be regarded solely as a marker of BBB integrity as has been 
suggested.20, 69 Whereas some claim that cerebral S100B originates from the astrocytic foot 
processes that enfolds the BBB,30 our data rather indicates that S100Bblood is a reflection of 
several factors of which merely one is the extent of BBBD. In a situation where the BBB is 
intact,69 it is therefore theoretically possible that the S100Bblood value is falsely low as this 
biomarker will then to some extent be “trapped” in the CSF. Applying a similar approach to 
NSE, we found that time from trauma was retained as the only significant independent variable 
in the model. This means that neither NSECSF nor QA were predictive of NSEblood. Our findings 
cohere with one previous study that did not find any increase of NSE following 
chemical/osmolytic BBBD.70 In summary, there was a clear relationship between QA and 
S100B, whereas for NSE there was not.  
 
Both our cross correlation and marginal/linear mixed model analyses hence indicate that S100B 
and NSE might be cleared differently from CSF to peripheral blood. There are however 
important differences in biochemical, kinetic, and/or pathophysiological properties between 
the two proteins, potentially confounding our results. Biologically, NSE is larger (39 kDa)71, 72 
than S100B (9-14 kDa),73 implications of which could be a swifter movement across body 
 
compartments for small proteins and longer serum half-life for larger proteins. Accordingly, 
NSE has been shown to exhibit an “effective half-life” of up to 48-72 hours in serum compared 
with 24 hours for S100B74, following severe TBI. This would give a slower decline of NSEblood 
values than S100B dittos. We compensated for this by employing an ARMA variance-
covariance structure to our model, however without finding any predictors of NSEblood other 
than time from trauma. Next, there are different sources for S100B and NSE throughout the 
body. S100B is present primarily in astrocytes,75 but extracranially also in muscle, bone, 
cartilage, adipose tissue and melanocytes.9, 76 The extracranial component is primarily of 
importance in multi-trauma patients during the first 12 hours following the trauma.8, 9 We 
excluded the first 12 hours from analysis for S100B and monitored patients for a week, which 
would result in a very limited contribution of extracranial S100B to our model. In contrast, 
whereas NSE intracranially locates primarily to neurons,9 extracerebral NSE emanate among 
else from erythrocytes.9, 77 Hence, extracerebral NSE is a confounding factor following both 
multi-trauma and hemolysis.9 Importantly, there is no clear period after trauma when this is 
important, but rather this potential confounder spans the entire data material and contributes a 
latent data noise. In summary, although S100B and NSE seem to have different clearance 
routes from the injured brain, there are differences between the proteins which may have 
influenced our results.  
 
Limitations 
The major limitation in this study relates to the inclusion rate (dependent on senior author 
presence) and the consequently small study sample size. Moreover, there are other factors 
which may be associated with brain biomarker clearance, such as brain injury severity or type 
of injury sustained, but these correlations necessitate a larger sample size to study. Conversely, 
 
the data was prospectively collected with a uniquely high temporal resolution with constant 
CSF drainage speed, therefore making this study highly relevant in term of brain protein 
clearance. Another limitation is that the CSF at time point 0 in our models constitutes a pool 
of CSF collected during the preceding 6 hours, thus the lag times could be slightly longer than 
indicated in the cross-correlations, though we believe the current protocol using the CSF pump 
is the most delicate way to extract CSF for serial sampling using an enclosed system. Further, 
in animals it has been shown that acetazolamide treatment, CSF drainage and sleep deprivation 
inhibits the glymphatic system.15 While no patients received acetazolamide and CSF drainage 
speed was constant in our study, all patients exhibited different levels of induced sedation 
which in theory could affect glymphatic clearance, but how this may affect biomarker levels in 
humans warrants further research. In spite of being a gold standard metric for BBBD, QA is 
age dependent,19 which is a source of error across all studies using it. Moreover, for TBI 
patients, intraventricular hemorrhage26 and administration of large amount of intravenous 
fluids could both affect QA. For the latter, we propose that CSF albumin alone might be an 
adequate surrogate for QA (and thus BBBD). Finally, in the injured brain, multiple factors are 
in play and it is possible that CNS half-life is discrepant from blood half-life of certain proteins. 
We do not account for this in our models, and in order to do so one needs to employ more 
extensive pharmacokinetic modeling, which will be the aim for future studies that are 
warranted. Another amenable avenue is radiological techniques67, 68 using biomarker specific 
contrast-enhancement combined with similar sampling techniques as ours in order to elucidate 




Blood biomarker levels of S100B and NSE correlate momentarily with BBB integrity, 
measured as QA. However, longitudinally, this relationship was stronger for S100B than NSE. 
Upon inferential modelling, blood levels of S100B were dependent on QA, which we could not 
observe for NSE. Although this could be due to underlying differences between the two 
proteins such as hemolysis of NSE, it indicates that S100B and NSE might be cleared 
differentially from the injured CNS, which is novel and important for brain biomarker 
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Table 1:  Reference intervals used 
Variable Reference interval 
AlbuminCSF [mg/L] 15-29 years: < 260 
³ 50 years: < 400 
Albuminblood [g/L] < 41 years: 36-48 
³ 71 years: 34-45 
QA [no unit] 15-29 years: < 0.006 
³ 50 years: < 0.009 
S100BCSF [µg/L] < 5 
S100Bblood [µg/L] < 0.11 
NSECSF [µg/L] < 13 
NSEblood [µg/L] < 18 
Reference intervals were defined as the reference intervals used by the Karolinska 




Table 2: Individual Patient Demographics  
Patient






AIS ISS Marshall Rotterdam Stockholm 
Brain injury 
progression GOS 
1 55 M 8 1 0 5 1 26 VI 5 3.7 0 4 
2 53 F 5 2 0 5 1 25 VI 6 3.6 1 3 
4 22 M 7 1 1 4 3 29 VI 6 3.3 0 3 
5 23 M 8 0 0 4 0 16 III 4 1.5 0 5 
6 20 M 8 2 1 3 2 17 II 3 1.8 1 5 
7 38 M 7 0 1 5 3 38 II 3 3.5 0 3 
8 25 M 8 0 0 5 0 25 IV 5 2 0 5 
9 42 M 3 1 1 5 3 38 II 3 1.5 1 3 
10 52 F 3 2 1 4 4 29 III 4 3.5 0 3 
11 59 M 7 1 0 5 0 25 VI 4 4.9 0 3 
12 62 M 3 0 0 5 0 25 II 3 2 1 1 
13 49 M 3 0 0 4 0 16 II 3 1.5 0 5 
14 20 M 7 0 0 5 0 25 VI 3 2.5 0 4 
15 36 M 7 0 1 4 3 26 III 4 2.8 0 4 
 
16 60 F 4 0 0 5 1 25 VI 4 2.5 0 4 
17 48 M 4 2 0 5 0 25 VI 5 3.8 1 1 
Demographic data of the patient cohort, depicted as each subject’s raw data value. One patient (#3) was excluded from all analyses due to a lack of 
albuminCSF samples.  
Clinical data upon admission 
Age [years]. Gender: M (male), F (female). GCS (3-15). Pupils, pupil responsiveness: 0 = bilateral responsive; 1 = unilateral unresponsive; 2 = bilateral 
unresponsive. Multitrauma: 1 = yes, 0 = no.  
Injury scores upon admission 
Head and non-head AIS: 1) minor, 2) moderate, 3) serious, 4) severe, 5) critical, 6) maximum. ISS (1-75).  
 
Classification upon admission CT 
Marshall: I) no visible pathology, II) diffuse injury, III) “swelling”, IV) shift, V-VI (“mass lesion”). Rotterdam: classes 1-6. Stockholm: tally-based. Brain 
injury progression: 1 = yes, 0 = no.  
 
Outcome data at 6 months follow-up 
GOS: GOS1) dead, GOS2) persistent vegetative state, GOS3) severe disability, GOS4) moderate disability, GOS5) good recovery. 
 
 
Abbreviations: AIS, Abbreviated Injury Scale; CT, computerized tomography; GCS, Glasgow Coma Scale; ISS, Injury Severity Score; GOS, Glasgow 
Outcome Scale; Marshall, Marshall CT score; NCCU, NeuroCritical Care Unit; pupils, pupil responsiveness; Rotterdam, Rotterdam CT score; Stockholm, 





Table 3: Inferential models of S100B and NSE clearance from CSF to blood 
Marginal model of S100B clearance Linear mixed model of NSE clearance 
Variable Estimate p value Variable Estimate p value 
Intercept -1.13 <0.001 Intercept 1.36 <0.001 
Time from trauma -3.82 <0.001 Time from trauma -0.0511 <0.001 
Time from trauma2 0.665 0.023    
S100BCSF 0.0247 0.008    
QA -0.0676 0.045    
Generalized linear model (marginal model) analysis showing how time from 
trauma, QA and S100BCSF were independent predictors of S100Bblood. In all 
analyses, the dependent variable was S100Bblood. The variables S100Bblood, QA, 
S100BCSF were log10-transformed. Time from trauma was used as a polynomial 
term with a degree of 2. The underlying correlation structure was modelled as an 
ARMA(1,1) process, for which the error term depends on the AR component j 
and the MA component q. These were estimated to be: j = 0.976 (CI: 0.955-
0.987) and q = 0.563 (CI: 0.456-0.654).  
Linear mixed model analysis showing how time from trauma was an independent 
predictor of NSEblood. In all analyses, the dependent variable was NSEblood. The 
variable NSEblood was log10-transformed. Random effects of the model was a 
random intercept (Patient) and a random slope (Time from trauma). The 
underlying correlation structure was modelled as an ARMA(1,1) process, for 
which the error term depends on the AR component j and the MA component q. 
These were estimated to be: j = 0.637 (0.454-0.768) and q = 0.621 (0.522-0.704).  








Figure 1: Temporal trajectory of biomarkers and QA in different compartments. 
S100BCSF was increased above the reference level (A) for all patients following injury and 
demonstrated a temporal decay. This was reflected in blood (C). For NSECSF (B), one patient 
demonstrated normal NSECSF values following TBI, and even more exhibited normal NSEblood 
values (D). AlbuminCSF was increased among roughly half of the patients (E) following the 
trauma, which was reflected upon in a pathological QA (F). Over time, there was a decay in the 
extent of albuminCSF and a decrease in QA, but interestingly, the extent of damage persisted 
throughout the whole study period for many patients. Dashed line: upper reference interval as 
used at the Karolinska University Hospital. Upper reference limit: S100BCSF < 5 µg/L, 
S100Bblood < 0.11 µg/L, NSECSF < 13 µg/L, NSEblood < 18 µg/L. For albuminCSF and QA there 
is an age dependent reference limit. Upper reference limits for albuminCSF: 15-29 years: < 260 
mg/L; ≥ 50 years: < 400 mg/L. Upper reference limits for QA: 15-29 years: < 0.006; ≥ 50 years: 
< 0.009. Abbreviations: CSF, cerebrospinal fluid; NSE, neuron-specific enolase; QA, albumin 
quotient.  
 
Figure 2: Cross correlations of biomarkers between compartments and QA. 
Cross correlations between BBBD/biomarkerCSF, BBBD/biomarkerblood, and 
biomarkerCSF/biomarkerblood are seen for S100B (A-C) and NSE (D-F). S100BCSF and 
S100Bblood had peak correlation at lag 1 (C), indicating that S100B is detected in blood 
approximately 12 hours later than in CSF. This could be attributed to the delayed clearance 
through the disrupted BBB (B). For NSECSF and NSEblood peak correlation occurred at lag 2, 
 
equivalent to 24 hours (F), but this could not be attributed to either intracranial NSE release (D) 
or any delayed clearance across the BBB of NSE (E). Overall, both S100B and NSE are detected 
later in blood than they are in CSF, and NSE is the slower of the two proteins. Each lag 
corresponds to 0.5 days. Dots correspond to mean cross correlation across a specific lag. Error 
bars consist of confidence interval (CI), where CI < 0 or CI > 0 reflect a significant cross 
correlation throughout that lag. Dashed lines harmonize lag 0 across all panels. Abbreviations: 
BBB, blood-brain barrier; BBBD, blood-brain barrier disruption; CSF, cerebrospinal fluid; 
NSE, neuron-specific enolase; QA, albumin quotient. 
 
 
Figure 3: Graphical depictions of clearance models for S100B and NSE. 
A marginal model (general least square estimation) was conducted for S100B (A) and a linear 
mixed model for NSE (B). Time from trauma, S100BCSF, and QA predicted S100Bblood in an 
additive model (A). In contrast, merely time from trauma predicted NSEblood (B). For both 
panels, the size of the circles denotes the biomarkerCSF value whereas the color gradient 
represents the value of QA. The black lines are the fitted values in each model. Abbreviations: 







Supplementary table 1: Cohort Demographics 
Variable Type [unit] Value, n = 16 
Age Years 45 (25-54) 
Male gender Count (%) 13 (81) 
Glasgow Coma Scale  7 (4-7) 
Pupil responsiveness Count (%) Bilateral responsive : 8 (50) 
Unilateral unresponsive: 4 
(25) 
Bilateral unresponsive: 4 
(25) 
Multitrauma Count (%) 6 (37.5) 
Head AIS Score (1-6) 1 (minor): 0 (0) 
2 (moderate): 0 (0) 
3 (serious): 1 (6.25) 
4 (severe): 5 (31.3) 
5 (critical): 10 (62.5) 
6 (maximum): 0 (0) 
Marshall CT Classification Classes I-VI I (no visible pathology): 0 (0) 
II (diffuse injury): 5 (31.3) 
III (”swelling”): 3 (18.8) 
IV (”shift”): 1 (6.25) 
V-VI (”mass lesion”): 7 
(43.8) 
Brain injury progression Count (%) 5 (31.3) 
Glasgow Outcome Scale Count (%) GOS1/Dead: 2 (12.5) 
GOS2/Persistent vegetative 
state: 0 (0) 
GOS3/Severe disability: 6 
(37.5) 
GOS4/Moderate disability: 4 
(25) 
GOS5/Good recovery: 4 (25) 
Patient demographics, described as summarized data for the whole cohort. Data is depicted 
as mean ± standard deviation (SD), or median (interquartile range [IQR]), if continuous. 
Categorical data is depicted as count (%). Abbreviations: AIS, Abbreviated Injury Scale; 
CT, computerized tomography. 
 
Figure Legends Supplementary Figures 
 
Supplementary Figure 1 (Figure S1): Sample Overlap in the Data. 
Depiction of all samples with and without sample overlap across key variables in the dataset. 
Each row/observation in the dataset represents one time point. CSF was sampled more 
frequently than blood and both biomarkers were sampled more frequently than albumin. 
Abbreviations: CSF, cerebrospinal fluid; NSE, neuron-specific enolase. 
 
Supplementary Figure 2 (Figure S2): Data Interpolation. 
Comparison of linear and loess interpolation over-layed together with the actually observed 
values (depicted in red) for one patient. The same patient is depicted across all panels. 
Abbreviations: CSF, cerebrospinal fluid; NSE, neuron-specific enolase. 
 
Supplementary Figure 3 (Figure S3): Temporal trajectory of blood albumin. 
Blood albumin levels were slightly decreased compared with normal reference intervals. Over 
time, the blood albumin values exhibited a discretely decreasing trend. Dashed line: lower 
reference interval as used at the Karolinska University Hospital. For albuminblood the reference 
limits were age dependent. Lower reference limit: < 41 years: 36 g/L; ³ 71 years: 34 g/L.  
 



